Healthpeak (DOC) Q4 2025 earnings review
Solid Q4 Results Overshadowed by Dismal 2026 Outlook
Healthpeak delivered a respectable Q4 with FFO as Adjusted of $0.47, capping a year of 4.0% Same-Store NOI growth. However, the narrative collapsed with the release of 2026 guidance. Management projects FY26 FFO of $1.70–$1.74, a sharp 6.5% decline at the midpoint from FY25. Even more concerning is the Same-Store NOI outlook of -1% to +1%, a dramatic deceleration from the +4% pace in 2025. The Lab segment has officially cracked (Q4 SS NOI -0.3%), and with the high-growth Senior Housing segment (Janus Living) being spun off, the remaining portfolio lacks the growth engine to offset Lab weakness.
🐂 Bull Case
The Outpatient Medical segment remains a fortress, delivering 4.1% Same-Store NOI growth in Q4 with robust 4.4% leasing spreads. New lease executions (288k sq ft) and high retention provide a defensive floor.
The planned IPO of Janus Living (Senior Housing) separates the highest-growth asset (+16.7% SS NOI in Q4) from the lagging portfolio. If the market values Janus at a premium multiple, shareholders could see immediate capital appreciation.
🐻 Bear Case
The Lab segment has turned from a laggard to a liability. Same-Store NOI turned negative (-0.3%) in Q4, and cash releasing spreads fell to -1.7%. With 2026 guidance implying continued struggles, the 'inflection point' narrative is losing credibility.
The Life Plan (CCRC) segment was the only true growth driver in Q4 (+16.7% SS NOI). By spinning this off into Janus Living, Healthpeak retains the stable-but-slow Outpatient assets and the contracting Lab assets, potentially trapping the remaining company in a low-growth value trap.
⚖️ Verdict: 🔴
Bearish. While Q4 execution was fine, the 2026 guidance indicates a structural earnings recession. Removing the high-growth Senior Housing business via spin-off leaves investors exposed to a Lab segment that is actively shrinking in profitability.
Key Themes
2026 Guidance Shock
Management's initial outlook for 2026 is significantly below recent trends. Forecasting FFO of $1.70–$1.74 (vs. $1.84 realized in 2025) and Same-Store NOI growth of -1% to +1% suggests the Lab segment's struggles are deepening just as interest expenses or other headwinds bite. This implies the 'bottom' for life sciences has not yet been found.
Lab Segment Fundamentals Turning Negative
For the first time in recent quarters, Lab Same-Store NOI turned negative (-0.3%) in Q4. More alarmingly, cash releasing spreads on renewals dropped to -1.7%. Despite management's claim that fundamentals are 'at or near an inflection point,' the data shows pricing power has evaporated.
Outpatient Medical Remains Resilient
The Outpatient Medical segment continues to perform as advertised, delivering consistent mid-single-digit growth (+4.1% SS NOI in Q4, +3.9% FY25). With 2.1M sq ft of total leasing in the quarter and positive spreads, this segment prevents a complete freefall in portfolio metrics.
Janus Living Spin-Off
The formation and planned IPO of Janus Living attempts to isolate the value of the Senior Housing portfolio. Given the 16.7% Q4 growth in this segment, the spin-off makes strategic sense to unlock value, but it significantly weakens the growth profile of the remaining Healthpeak entity (RemainCo).
Capital Recycling Activity
The company remains active in recycling capital, acquiring the $600M Gateway Crossing campus while disposing of ~$325M in outpatient assets. However, selling stabilized outpatient assets to buy into a Life Science market that is currently showing negative spreads adds execution risk.
Other KPIs
Stable. Came in slightly ahead of the $0.46 reported in Q4 2024. Full year result of $1.84 beat the high end of the Q3 guidance range ($1.81–$1.87), showing decent operational execution in 2025 despite the looming 2026 headwinds.
Stable. Leverage remains well-managed and within target range, providing capacity for the $1B capital recycling plan mentioned in strategic updates. Liquidity is not a concern.
Accelerating. Up from 12.0% in Q3 2025. This segment is firing on all cylinders, which ironically highlights the risk to Healthpeak shareholders if the Janus Living IPO does not command a premium valuation to compensate for the loss of this growth engine.
Guidance
Reversing. Represents a ~6.5% decline from the $1.84 achieved in 2025. This indicates that the loss of NOI from dispositions, the Janus spin-off costs, or Lab vacancy issues are outweighing any organic growth.
Decelerating. A massive drop from the +4.0% achieved in 2025. This range implies that Outpatient Medical growth (likely ~3%) will be entirely negated by significant contraction in the Lab segment.
Key Questions
Lab Segment Inflection Verification
You state that life science fundamentals are 'at or near an inflection point,' yet Lab SS NOI turned negative in Q4 and renewal spreads were -1.7%. What specific data points in your pipeline give you confidence that 2026 won't see further deterioration?
2026 Guidance Bridge
FFO is guided down ~6% and SS NOI is guided to flat. Can you bridge the specific headwinds causing this drop? How much of this is driven by the Lab segment specifically versus transaction impacts?
Janus Living Spin-Off Rationale
With Life Plan (Janus) being the only segment delivering double-digit growth, does spinning it off leave the remaining company (Healthpeak) as a low-growth yield co? How do you plan to re-accelerate growth in RemainCo without the Senior Housing tailwind?